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Abstract 
SINGLE NUCLEOTIDE POLYMORPMSMS IN THE FOLYLPOLY- GAMMA- 
GLUTAMATE SYNTHETASE GENE 
By Nadine Thompson, B .S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006. 
Major Director: Richard G. Moran, Ph.D. 
Professor, Pharmacology and Toxicology 
Folic acid is an essential vitamin utilized in the one-carbon metabolism pathway for the 
synthesis of purine and thymidine nucleotides, which are necessary for cell growth and 
proliferation. As a result, the enzymes that participate in the metabolism of folic acid 
have been good targets for cancer chemotherapy. Folylpoly-y-glutamate synthetase 
(FPGS) is an enzyme in the folate metabolism pathway that catalyzes the addition of 
glutamic acid to the naturally occurring folates, thereby allowing the retention of folate 
cofactors in cells. Similarly, in the case of cancer chemotherapy, antifolates, such as 
Lometrexol and Tomudex are retained in cells through the activity of FPGS. 
Consequently, any single nucleotide polymorphisms (SNPs) that exist in the f igs  gene 
may decrease or increase the cytotoxicity of antifolates and, ultimately, the clinical 
response rate to antifolate therapy. The goal of this project is to define the position and 
frequency of single nucleotide polymorphisms (SNPs) in the mRNA made from the f igs  
gene from peripheral blood of one hundred normal individuals. Six Polymerase Chain 
Reaction (PCR) primers were designed to amplify the gene as three overlapping pieces 
and four primers were designed for sequencing of the three PCR products. In this study, 
we found polymorphic sites at nucleotides 64, 123, 253, 423, 1334 and 1781. The 
majority of the samples (49188) expressed mRNA with point mutations on at least one 
allele at base 64, while 8 samples had a SNP at base 123. At nucleotide 123, 6 samples 
expressed the heterozygote GIA genotype, and one sample expressed the homozygote 
A/A allele at this site. At nucleotide 423, two samples expressed a G allele and also the 
common C allele. While the SNPs at nucleotide 64, 123, and 423 caused a silent or 
conservative mutation in the gene, in sample 82, a mutation C253T produced an amino 
acid change from an arginine to tryptophan, which may cause a functional change in the 
fpgs protein, due to the significant change in size and charge of the wild type amino acid. 
Similarly, sample 26 expessed a homozygote TIT allele at nucleotide 1334 instead of the 
common CIC allele expressed in the remaining samples. This point mutation caused a 
valine to alanine amino acid change. We also detected a SNP that is expressed after the 
stop codon in sample 40. 
Chapter 1 
INTRODUCTION: 
Single Nucleotide Polymorphisms 
Single Nucleotide Polymorphisms (SNPs) are point mutations that exist within the 
genetic code of every individual (1). The four nucleotides, adenine (A), thymine (T), 
guanine (G), and cytosine (C), serve as the building blocks for the DNA sequence coding 
for the RNA message during transcription. A Single Nucleotide Polymorphism occurs 
when one nucleotide, such as adenine for example, is replaced by another nucleotide such 
as thymine, guanine or cytosine. This change in the DNA sequence may appear on one or 
both alleles of a gene, producing a homozygous (altered sequence of both alleles) or 
heterozygous (altered sequence of one allele) mutation. As one can imagine, a significant 
change in the sequence of a gene that alters the protein sequence encoded by the RNA, 
ultimately affects protein size andfor function, which can have dramatic effect on cellular 
activity and function. Since all amino acids are coded by more than one codon, it is 
possible to have a SNP that creates a new codon that translates to the same amino acid. 
For instance, the nucleotide triplets AAA and AAG both result in insertion of a glutarnic 
acid to a growing peptide codon. This 'silent' substitution normally occurs with a single 
base change in the third position of the codon. In some instances, however, a base 
change in the third position may cause a nonconservative change, where one amino acid 
replaces another amino acid with dissimilar chemical characteristics. For instance, 
mutation of the triplet, TGT to TGG would change the encoded amino acid from cysteine 
to tryptophan. Similarly, base changes in the first and second position of the codon can 
result in several types of different mutations. A nonsense mutation occurs when a SNP 
causes an amino acid change that results in a stop codon. A missense mutation, on the 
other hand, occurs when a SNP results in the replacement of an amino acid by one of 
similar chemical nature, which does not alter protein function. For example, mutation of 
the nucleotide triplet GAC to GAA would cause an amino change from aspartic acid to 
glutarnic acid. This phenomenon, of amino acid substitution and protein function 
modification, is particularly important in disease diagnosis and drug therapy, where a 
point mutation may signify a disease state or may alter protein function in a way that 
enables cells to become resistant or insensitive to certain drugs. It is difficult to 
determine the number of single nucleotide polyrnorphisms that exist in each gene within 
the human population, information that would require a complete sequence analysis of 
the entire human genome across the entire human population. In fact, the complete 
sequence of the entire genome of a single individual has only recently been completed 
(2). Surprisingly, the human genome consists only of about 30,000 genes spanning 23 
pairs of chromosomes, far below the original estimates of 150,000-250,000 (3). This 
number is surprisingly low when compared to the number of genes found in species that 
are much less complex than humans. The genome of C. elegans, for example, consists of 
19,099 genes while D. melanogaster and S. cerevisiae have only 13,061 and 6,034 genes, 
respectively (3). The estimated number of genes for M. musculus is roughly the same as 
in humans (2). It appears that the mechanism by which the human body maintains it 
complexity with a limited number of genes involves gene splicing, gene rearrangement, 
andtor expression of multiple transcriptional start sites that allows one gene to code for 
multiple proteins or multiple forms of one protein performing entirely different functions. 
Multiple transcriptional start sites in the folypoly-y-glutamate synthetase gene, for 
example, allows the transcription of two forms of FPGS mRNA corresponding to two 
isoforms of the FPGS enzyme (4) (See Figure 1). 
SNPs in the genes of folate metabolism 
The folylpolyglutamate synthetase enzyme (FPGS) plays a central role in intracellular 
accumulation of folate and antifolate in the cytosolic and mitochondrial compartments of 
the cell (5). Two translational start sites, one for the mitochondrial FPGS and the other 
for the cytosolic FPGS, exist within thefigs coding region, allowing the gene to code for 
two proteins that function in two different compartments (cytosol and mitochondria) of 
the cell. The cytosolic and mitochondnal proteins are extremely important for cell growth 
and survival, and so as one can imagine, if a single nucleotide polymorphism exists in an 
essential part of the coding region of thefpgs gene preventing correct translation of the 
mitochondnal or cytosolic protein, then cell death could occur. Recent studies have also 
shown a variation in the frequency of single nucleotide polymorphisms across different 
populations of people (4). For example, the methylenetetrahydrofolate reductase 
(MTHFR) gene was shown to have several polymorphic sites that appear more frequently 
in certain populations of people. A C+T polymorphism at nucleotide 677 of the mt& 
gene caused a change of the alanine to a valine amino acid, while an A+C 
polymorphism at nucleotide 1298 caused a change in sequence from alanine to glutamate 
at this site (7). While only 1 percent of the Black population in the United States, sub- 
Saharan Africa, and South America, for example, expressed the TT genotype of mthfi; 20 
percent of US Hispanics, Colombians, and Amerindians in Brazil expressed this genotype 
(8). Polymorphisms at nucleotide 1298 in mthfr are fairly common. White populations in 
Europe, North America, and Australia showed 8-20 percent expression of the TT 
genotype for the mthfr gene, and 12 percent of the Japanese were homozygous for this 
allele (8). Another important protein of folate metabolism, 5-methyltetrahydrofolate- 
homocysteine methyltransferase (mtr), expressed an A 3 G  polymorphism at nucleotide 
2756 in codon 919, which caused the replacement of aspartic acid with glycine, changing 
the function of this enzyme, and ultimately causing a decrease in plasma homocysteine 
level (9). This residue occurs in the substrate-binding region of the protein. A small 
percentage (2-3) of Japanese, Chinese, and Korean populations expressed the GG 
genotype at the mtr gene, while, in the African-American population, six percent had the 
GG genotype. Of Canadian Caucasian children and their mothers and in the Caucasian 
population in Hawaii, 10-1 1 percent were GG homozygotes at nucleotide 2756 in the mtr 
locus (10). Findings from studies such as these that analyze genetic variation across 
different populations of people are necessary to understand why a certain population is 
more suscemble to certain diseases and how these patients will react to varying degrees 
of drug therapies. In the case of the methylenetetrahydrofolate reductase (mthfl gene, for 
example, it was found, that heterozygotes expressing the C+T variant at nucleotide 677 
on one chromosome have 10 percent lower red cell folate levels compared with CC 
homozygotes, and TT homozygotes produced 18 percent lower red cell folate levels (11). 
Individuals expressing the TT genotype also had lowered vitamin B12 and plasma folate 
levels. In the case of the MTR protein, where the A/G polymorphism at position 2756 
replaces aspartic acid with glycine in the protein substrate-binding region, studies show a 
lowered plasma homocysteine level in individuals expressing the GG allele than those 
expressing the more frequent A allele. Another study found that individuals expressing 
the GG genotype in the mtr gene appear to produce significantly higher plasma folate 
levels, than those expressing the AA genotype (12). Variation in expression levels of 
different proteins, especially those targeted for drug therapy, can affect the efficiency of 
drug interaction with their target proteins. 
Enzymes of the Folate Metabolism 
There are currently a number of different chemotherapy drugs on the market that target 
several proteins in the folate metabolism pathway. This pathway consists of a series of 
one-carbon transfer reactions that result in the production of purine and thymidine 
nucleotides necessary for DNA synthesis, amino acid metabolism, and the formation of 
the methyl-donating agent, S-adenosylmethionine (SAM) (See Figure 2) (8). Once 
folates are absorbed from the diet in the gastrointestinal tract, they pass through the liver 
and blood stream. Folates then cross the cellular membrane through an active carrier- 
mediated transport system, which binds reduced folate compounds. There are two forms 
of carrier-mediated transport system utilized by the cell for intracellular transport of 
reduced folates. The first is the low affinity reduced folate carrier, which has affinity 
constants in the micromolar range for its endogenous substrates 5-methyltetrahydrofolate, 
5-formyltetrahydrofolate, and the antifolate, methotrexate (13). The second transporter 
system employs a folate-binding protein, called the human folate receptor (hFR), which is 
associated with the outer membrane of the cell (14). This system has a much higher 
affinity for reduced folates, with affinity constants in the nanomolar range. Once folic 
acid enters the cell, it is reduced to dihydrofolate, which is then reduced to 
tetrahydrofolate (THF) through the catalytic activity of the enzyme, dihydrofolate 
reductase (See Figure 2). Another reduced form of folates, 10-formyltetrahydrofolate, 
serves as the donor of the single carbon group in the de novo biosynthesis of purine 
nucleotides. Intracellular retention of folates in the cells occurs through the catalytic 
activity of the enzyme, folylpolyglutamate synthetase (FPGS). Once folates are 
polyglutamated and reduced to THF, they are converted to 5,10 
methylenetetrahydrofolate. The 5,10 methyleneTHF then undergoes two separate 
enzymatic reactions. In the first reaction, 5,10 methyleneTHF is reduced to 5-methyl- 
THF by methylene tetrahydrofolate reductase (MTHFR), subsequently allowing the 
transfer of the N-5 methyl group from 5-methyl-THF to homocysteine, which results in 
the synthesis of methionine. Methionine synthesis requires the coenzyme vitamin B-12, 
the acceptor of the methyl group from 5-methyl-THF, and the enzyme methionine 
synthase. Once methionine is synthesized, it converts to S-adenosylmethionine (SAM), 
which serves as a source of a methyl group during DNA methylation and other 
methyltransferases reactions. The second enzymatic reaction involving the 5,10 
methylenem cofactor results in the synthesis of thymidylate by the enzyme 
thymidylate synthase. In this reaction, 5,10 methyleneTHF serves as the donor of the CH2 
unit, which is passed to the 5& position of deoxyuridylate and reduced in the thymidylate 
synthase reaction. Thus, thyrnidylate synthase functions as the enzyme that catalyzes the 
transformation reaction of 2'-deoxyuridine-5-monophosphate ( d m )  to 2'- 
deoxythymidine-5'-monophosphate (TMP) which is then phosphorylated by cellular 
kinases and integrated into DNA. Thymidylate synthetase also causes the oxidation of 
5,10 methylenem to dihydrofolate, which must then be converted back to 
tetrahydrofolate by DHFR. These one-carbon transfer reactions of the folate metabolism 
pathway are all required for cell growth, and, hence, this pathway is a good target for 
antiproliferative drug therapy. 
Inhibitors of Folate Metabolism 
Antifolates are folate analogs that inhibit various points of the folate metabolism 
pathway. Some of the classical antifolates, which are inhibitors of dihydrofolate 
reductase and thymidylate synthetase, are methotrexate, pemetrexed, and tomudex (See 
Figure 3) (15). Methotrexate, a competitive reversible inhibitor of Qhydrofolate 
reductase, differs from folic acid in that an amino group is substituted for the hydroxyl 
group at the 4' position of the pteridine ring. This structural change increases the 
binding affinity of the drug to the folate-binding pocket of DHFR, making it more 
dificult to displace the drug from the enzyme (16). Binding methotrexate to 
dihydrofolate reductase causes a decrease in the intracellular reduced folate pools and an 
increase in dihydrofolate. The retention of methotrexate inside the cell is due to activity 
of folylpolyglutamate synthetase, which attaches up to six glutamate molecules to the 
pteridine ring of the antifolate, causing a net trapping effect of the drug inside the cell. 
Tomudex, another antifolate, is a selective inhibitor of thymidylate synthetase (TS) (17). 
Tomudex, which interferes with the enzymatic activity of thymidylate synthetase, causing 
a decrease in thymidylate production and DNA synthesis, and is currently being used in 
therapy of colorectal cancer (17). Pemetrexed is also a potent inhibitor of thymidylate 
synthetase and DHFR that accumulates inside the tumor and is retained intracellularly as 
a result of polyglutamation by folylpolyglutamate synthetase (18). 
Folate and Antifolate Polyglutamation 
Reduced folates bind more tightly to their corresponding enzymes when in a 
polyglutamated state than in a monoglutarnated state (15). Similarly, the binding affinity 
of antifolates to their target enzymes increases, as they are polyglutamated by FPGS. The 
structure of the FPGS enzyme with its folate and antifolate binding sites is illustrated in 
Figure 4. Consequently, as these drugs are retained inside the cells, their cytoxicity is 
prolonged and their ability to inhibit cell growth and proliferation improves. Furthermore, 
previous studies have shown that tumor cells that have partially inactivating mutations in 
FPGS are resistant to most antifolates (19). For these reasons, FPGS plays central role in 
trapping of intracellular antifolates, and is viewed as critical to the efficacy of antifolate 
chemotherapy. 
Folylpolyglutamate Synthase 
Human folylpolyglutamate synthetase gene is located on human chromosome 9q34 (20). 
The rnRNA consists of 2475 base pairs spliced from 15 exons and the entire gene spans 
11.2 kb of genomic DNA (21). FPGS cDNA isolated from T-acute lymphocytic 
leukemia cells (CEM) encodes a protein with 545 amino acids that has a MW of 60 Kd. 
The transcription of the humanfigs gene results in the production of two separate mRNA 
variants that code for a cytosolic and a mitochondnal isoform of the FPGS protein (4). 
The cytosolic isoform has a shorter N-terminus than the mitochondrial isoforrn, and lacks 
the upstream mitochondnal leader sequence found in the mitochondrial isoform. The 
transcriptional leader sequence of the mitochondrial construct allows the transport of 
FPGS protein to the mitochondnal matrix compartment of the cell, where FPGS is 
required for mitochondnal folate accumulation. 
Accumulation of folates inside the cytosolic and mitochondria1 compartments of the cell 
allows for the survival and maturation of proliferating cells. Any significant mutation in 
the fpgs gene might prevent intracellular accumulation of folates, which affects cell 
growth and cell survival. In the case of antifolate drugs, a mutation in thefpgs gene will 
negatively impact proteiddrug interactions, thereby preventing intracellular accumulation 
of the antifolates (19). 
Previous reports of SNPs in the human fpgs gene 
There are currently a number of single nucleotide polymorphisms in the figs gene that 
have been reported in the NCBI SNP database. The NCBI SNP database, which was 
established by the National Human Genome Research Institute and the National Center 
for Biotechnology Information, is a readily accessible repository of single nucleotide 
polymorphisms from genes that have been sequenced worldwide. The genetic 
polyrnorphisms (including nucleotide substitutions, deletion, and insertions) that have 
been submitted to the SNP database come from random sequencing performed manually 
or robotically in different laboratories. Because many of these randomly submitted SNPs 
have not yet been confirmed by further studies, it is difficult to distinguish true SNPs 
from sequencing errors. Table 2 is a compilation of all 37 unique SNPs that have been 
submitted to the NCBI database since July 2006. Of the 38 SNPs submitted, 27 of them 
were detected in the introns and 8 were detected in the exons of the gene. While two of 
the SNPs submitted were never detected on the figs locus by Blast search, four of the 
intronic SNPs were from unknown regions of the intron. Of the 8 exonic SNPs reported, 
four were detected in exon 15, one in exon 16, one in exon 1 1, and two were detected in 
exon 1. Three of the SNPs detected in exon 15 were from the 3'untranslated region 
(UTR) of the gene. Only two of these SNPs, located in the 3'untranslated region of the 
Jigs locus, were later confirmed in other studies. SNP entry # rs4451422 was later 
confirmed in a study performed on 354 samples. The heterozygote A/C allele and the 
homozygote A/A and C/C alleles were detected at a frequency ratio of .065 1.234/ .333 
respectively. The remaining .367 allelic frequencies were unspecified in the Database 
(see NCBI Database). SNP entry # rs10 106 was also later confirmed in a study conducted 
using 421 samples. The heterozygote AIG allele and the homozygote A/A and G/G 
alleles were detected at a frequency ratio of .48 1.22 / .30 respectively. The remaining 
SNP, founded in exon 15 (entry # rs12686275), which caused an amino acid changed 
from valine to aspartic acid was never confirmed in a study done using 209 samples. For 
this reason, SNP entry # rs12686275 appears to be the result of an error in the sequence. 
Similarly, SNP entry number rs1042304, of uknown intron, was checked in a study done 
using 204 samples and was never detected. This SNP also seems to be a sequencing error. 
Of the three SNPs detected in exon I ,  SNP entry # rs17855899 and # rs10760502, found 
in codon 22 and which caused an isolucine to valine amino acid change, was submitted 
two times to the NCBI database. This SNP was later detected in 55% of the samples used 
in this study. SNP entry #rs2230270 of exon 11 that resulted in a threonine to alanine 
amino acid conversion has also been confirmed by a study done using 23 samples. The 
alleles detected from this study were homozygote A/A and heterozygote A/G at a 
frequency of 95.7% and 4.3% respectively. Entry # rs11554717 was another SNP that 
was detected in exon 1 of codon 2 1. This SNP caused an A to C polymorphism, which 
did not change the glycine amino acid of the protein. This SNP has not yet been 
confirmed. Similarly, SNP # rs17855900, which caused a C to T polymorphism that 
changed the valine to an alanine and has not yet been confirmed. Both these unconfirmed 
SNPs appeared as a result of random sequencing. The intronic SNPs that have been 
confirmed are entry # rs7856096 and rs955171. SNP rs7856096 was confirmed in a 
study performed on 209 indviduals. In this study the alleles detected were A/A, A/G, 
and GG at a frequency ratio of .885 / .091 / .024 respectively. Similarly, SNP rs955171 
was confirmed in four studies. Three of these studies had 100% C/Cs in all 30 samples 
while the other study had 100% G/G in all 47 samples. Reasons for the discrepancy in 
these two results are unknown. 
In the current experiment, we have detected a number of single nucleotide 
polymorphisms in thefpgs gene that may cause significant functional differences in the 
FPGS protein. The first portion of these experiments involves the isolation of RNA using 
the Trizol method and sequencing of PCR products from three control cell lines with a 
known polymorphic site at nucleotide 64 in exon 1 of the gene. The next portion of the 
experiment involves isolation of RNA from 100 patient samples using the Quiagen 
method, which we found to be less time consuming, and direct sequencing of the PCR 
products to determine the presence of polymorphisms. For the 100 patient samples, RNA 
integrity and concentration was determined using the microchip on the Agilant 
Bioanalyzer. Sequencing was done at the DNA core lab at the Virginia Commonwealth 
University and at the SeqWright and Fisher Scientific Laboratory, and single nucleotide 
polymorphisms were detected using the Codoncode Aligner computer program. All 
polymorphisms presented have been confirmed through repeated experiments across a 
number of different samples. 
Fig 1. Transcriptional start site for human fpgs 
The entire humanfpgs mRNA construct consisting of 2487 nucleotides is displayed in 
Figure 1. Two translational methionine start sites (as shown in blue, along with the stop 
codon) were detected in this region of the human&gs mRNA by PCR-derived RACE (4). 
The first methionine site signals the initiation of translation of the leader sequence of the 
mitochondrial F'PGS protein, while the second methionine site signals the start of 
translation of the cyosolic F'PGS enzyme. The 3' untranslated region of the mRNA 
construct consists of 50 nucleotides and the 5' untranslated region consists of 673 
nucleotides. The mitochondria1 fpgs mRNA consists of 1765 nucleotides and the 
cytosolicfpgs mRNA consists of 1643 nucleotides of the coding (21). These data were 
reproduced fiom GenBank entry NM 003056 (www.ncbi.gov). 
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96 1 ccaacgccgc cttggccttg cagctggccc actgctggct gcagcggcag gaccgccatg 
1021 gt- gc(=wg= tcwww3 aiFtc@a gcagctgw Q3g-g 
108 1 tgttccagcc cacatcccac atgcggctcg ggcttcggm cacggagtgg ccgggccgga 
1 14 1 cgcaggtgct gc&%cgcggg cA3xtcacct ggtaccQga c~g~gcgc= accgCCBg- 
120 1 gcgcgcaggc ctgcgtgcgc tggttccgcc aggcgctgca gggccgcgag aggccgagcg 
126 1 gtggccccga ggttcgagtc ttgctc- atg-a gga=gggac =ggcggccc 
132 1 tgctgaagct gctgcagccc tgccagtttg actatgccgt cttctgccct aacctgacag 
138 1 aggtgtcatc cwaggcaac gcagacwm agaac#cac agtgacactg gaccaggtcc 
144 1 tgctccgctg cc%lzaacac cagcw=t gfw-t &Wgaagag w3gccagcc 
1501 cggacctctg gagtgccccc agcccagagc ccggtgggtc cgcatccctg Mggcgc 
156 1 cccacccacc cacawtgc agtgccagct ccctcgtctt cagctgcatt tcacatgcct 
1621 tgaatggat cagccaaggc cgagacccca tctbxagcc acctagtccc ccaaagggcc 
168 1 tcctcaccca ccctgtggct cacagtgggg ccagcatact ccgtgaggct gctgccatcc 
174 1 atgtgctagt cactggcagc ctgcacctgg tgggtggtgt cctgaagctg ctggagcccg 
1801 cactgtccca gtas- ccwmm @mggag  - ctgcctgcgt 
1 86 1 tctccccatg aactlmxh ctaggtgcct mgmttg gctttcctgg ttctgtctag 
192 1 wtggcctag gggccagsc wggw3g !!Pggccggga gaggatgtct mttaaggc 
19 8 1 tctgtgcctt ggtctctcct tcctcttggc tgagatagca gaggggctcc ccgggtctct 
204 1 cactgttgca gtggcctggc cgttcagcct g tc tccm acaccccgcc tgcctcctgg 
2 10 1 ctcaggccca gcttattgtg tgcgctgcct ggccaggccc tgggtcttgc catgtgctgg 
2 16 1 gtggtagatt tcctcctccc agtgccttct -gag agggcctctg cctgggacac 
222 1 tgca-g aI3gegctg &agtgaatta ~~Wst - a a s w w  
228 1 ccttcgactg acccttgacc ccctgctccc tcagcagaga cggagggagg ggctgctggt 
2341 $5f@c4zggac ctgcactgtg tagagggagc cQsa3w g g c d m  w- 
240 1 ctccctgtgc gcctcaggtg gcctgtctgt gagatgagaa gaagaccaga ctgaagcctg 
2461 ttmaaatat gccaggcagt gcmct 
Fig. 1 
Fig 2. Folate Metabolism Pathway 
Folic Acid is utilized in the folate metabolism pathway, which consists of a series of one- 
carbon transfer reactions that result in DNA synthesis and DNA methylation. Folic acid 
enters the folate metabolism pathway as its reduced form, dihydrofolate, which ultimately 
reduces to 5,lO-methyltetrahydrofolate through the enzyme 5,lO-methyltetrahydrofolate 
reductase. 5,lO-methyltetrahydrofolate then enters the thymidylate synthase pathway 
where it plays a central role in the conversion of deoxyuridine monophosphate to 
deoxythymidine monophosphate in the synthesis of purine and thymidine nucleotides. 
Similarly, 5-methyltetrahydrofolate (a reduced form of tetrahydrofolate) plays a central 
role in the formation of the methyl donating agent, S-adenosylmethionine (SAM) in the 
DNA methylation pathway. This diagram was moQfied from Sharp, L et a1 (6). 
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Fig 3. Classical Antifolates 
Three classical antifolates used for cancer chemotherapy are methotrexate, pemetrexed, 
and tomudex. Due to their structural similarities to folates, these folate analogs serve as 
effective inhibitors of folate metabolism. Methotrexate is a competitive reversible 
inhibitor of dihydrofolate reductase, whose increased binding affinity to dihydrofolate 
reductase causes a decrease in the intracellular reduced folate pools. Similarly, tomudex 
when bound to thymidylate synthase, inhibits its enzymatic activity, thereby decreasing 
thymidylate production and DNA synthesis. Pemetrexed, also an antifolate that is 
structurally similary to folic acid, inhibits both thymidylate synthase and dihydrofolate 
reductase, preventing DNA and RNA synthesis (15). 
Tomudex 
Pemetrexed 
Fig. 3 
Fig 4. Ribbon structure of the Lactobacillus casei FPGS enzyme 
In order to fully understand the clinical significance of SNPs in the fpgs gene and its 
effect on antifolate therapy, extensive research on the structure of the FPGS enzyme must 
be conducted. The position at which amino acid changes occur in the polypeptide chain 
determines the degree by which they would affect the enzymatic activity of the protein. 
An amino change in the active site, for example, would greatly affect the catalytic 
activity of the enzyme versus an amino change on the outer surface of the enzyme. 
Figure 4 illustrates the ribbon structure of the Lactobacillus casei FPGS enzyme. The 
blue a.rea of the structure represents the N-terminal of the FPGS protein, which is 
composed of a ras-like domain and a three-stranded P-sheet (shown in green) (22). The C- 
terminal of the enzyme, which appears to contain the folate-binding cavity, is illustrated 
by red portion of the structure. The ATP-binding P-loop motif of the enzyme is 
highlighted in magenta, and next to the ATP-binding P-loop motif lies the fl loop, which 
serves as the active site of the enzyme, and is highlighted in cyan. Thin black lines 
represent the joining of the breaks in the polypeptide chain, and the alph-helix A10 of the 
enzyme is highlighted in pink (22). 
Pig. 4 
Chapter 2 
MATERIALS AND METHODS 
Cell Line and Culture 
Three human tumor cell lines, CEM (lymphoblastic leukemia cells), MCF-7 (breast 
cancer cells), and WIDR (colon carcinoma cells) were grown in RPMI-1640 medium 
supplemented with 10% fetal bovine serum and maintained at 37" in 5% C02 Cell counts 
were determined using tryptan blue and a hemocytometer. 
RNA Isolation: Control Samples 
RNA from three control cell lines, CEM, MCF-7, and WIDR, was extracted using Trizol 
reagents from Invitrogen Life Technologies. In a 15 ml tube, Trizol was added to cell 
pellets at a ratio of lml of Trizol 1 1.4 x lo7 cells and the cell suspension was vortexed for 
1 minute to homogenize the cells and extract the nucleic acids. The mixture was then 
incubated for 3 minutes at room temperature and 0.2 ml of chloroform/lml of Trizol was 
added. The mixture was vortexed for 15 seconds, and incubated for 15 minutes at room 
temperature. The samples were then centrifuged at 12,000 g for 15 minutes and the 
aqueous phase was transferred to a new Eppendorf tube. Isopropanol was added and the 
tubes were centrifuged at full speed in a Beckman microfuge for 10 minutes at 4 ' ~ .  Each 
cell pellet was then washed with 500 p1 of 70% ethanol and the suspension was 
centrifuged at full speed for 2 minutes in a cold room. The pellet was air dned for 10 
minutes and then dissolved in 50 p1 of diethyl pyrocarbonate (DEPC) water. The RNA 
concentration and RNA purity were estimated by spectrophotometry (using a Spectronic 
Genesys 5 spectrophotometer), by adding 5 p1 of sample and + 95 p1 Tris-EDTA buffer 
(TE) and determining the absorbancy at 260 nm and 280 nm. RNA concentration was 
determined using the Beer-Lambert law which state that A= E C1 (A=Absorbancy at a 
particular wavelenth, E = Extinction coefficient, C =Concentration and 1 = path length of 
spectrophotometer cuvette in centimeters). An A260 reading of 1.0 is equivalent to 40 
pg/yl of RNA. An aliquot (1 pl of the 50 p1 solution) of each RNA sample was then run 
on a 1 % denaturing agarose gel to assess RNA integrity. 
RNA Isolation: Patient Samples 
Samples of peripheral blood were obtained from Carleton Garrett, M.D, Catherine 
Dumur, PhD and Amy Ladd, PhD, of the Molecular Diagnostics Laboratory of Virginia 
Commonwealth University. Ail samples were drawn with informed consent and were 
supplied for this study anonymously by Carleton Garrett, M.D. Peripheral blood was 
collected from 100 normal patients and mononuclear cells (MNC) were isolated using the 
Ficoll-Paque Plus technique. RNA was extracted from the cell pellets using the Qiagen 
RNAse easy kit and following the protocol suggested by the manufacturer. Cells were 
lysed using 350 p1 of Buffer RLT, a buffer containing guanidinium isothiocyanate and 13- 
mercaptoethanol, and the cell suspension was vortexed until no cell clumps remained in 
the sample. The lysate was then washed using 350 p1 of 70% ethanol to ensure sufficient 
RNA binding to an RNeasy silica-gel membrane of the mini column (used as a device to 
remove RNA contaminants). Following washing of the lysate with ethanol, 700 p1 of 
sample was then added to the RNeasy mini column and the mini column was centrifuged 
for 15 seconds at 12,000 rpm. To remove contaminants from the RNA, additional 
washing of the RNA on the mini column was done using 700 p1 of RWl and 500 pI of 
Buffer RPE and the mini column was centrifuged for 15 seconds at 12,000 rpm after each 
addition. The columns were then removed and placed in a collection tube and the mini 
column was then centrifuged for 2 min at maximum speed to dry the membrane. For 
complete elution of the RNA from the columns, 25 p1 RNase-free water was applied 
directly to the filter of the column, let stand for 5 minutes at room temperature and 
centrifugation at 12,000 rpm for 1 minute. An aliquot (1 p1) of Rnase irhbitor was added 
to each sample to prevent RNA degradation. The RNA concentration and RNA purity 
was estimated by spectrophotometry by adding 5 ul of sample and + 95 p1 TE and 
determining absorbancy at 260 nrn and 280 nm. 
Quantification of RNA and Assaying RNA Integrity 
To assess the integrity of total RNA, lul from each sample was loaded and ran on a chip 
of the Agilent 2100 Bioanalyzer. The Agilent 2100 Bioanalyzer produces an 
electropherogram that displays two peaks corresponding to the 18s and 28s ribosomal 
RNAs that one usually observes on denaturing agarose gel (See Figure 6). We were able 
to determine the intemty of the RNA based on the height and quality of peaks 
representing the 18s and 28s ribosomal RNA displayed by the Agilent 2 100 Bioanalyzer. 
Two distinct peaks appearing on the electropherogram represent pure RNA while 
multiple small peaks represent RNA degredation. 
First-strand cDNA Synthesis 
First-strand cDNA synthesis was done using the Invitrogen Superscript I1 kit. Two 
reaction mixtures were prepared in a 0.5 ml tube. The first reaction mixture (RNARrimer 
mix) consists of total RNA template (3 ug), random hexamers (.2 ug), lOmM 
deoxyribonucleotide triphosphates (cLNTPs), plus an added volume of nuclease-fiee water 
to achieve total desired RNA concentration. This mixture was then incubated at 65OC for 
5 minutes and chilled on ice for at least lminute. The second mixture (cDNA synthesis 
mix) consisted of 2 p1 of lox RT Buffer (consisting of 0.5 M Tris-HC1 , 0.75 M KC1, 
0.03 M MgC12), 4 p1 of 25 mM MgC12, 2 pl o f .  1 M DTT, and 1 pl RNaseOUT (4U / pl). 
An aloquot of the cDNA synthesis mixture (9 p1) was then added to each tube of 
RNA/Primer mix and the tubes were gently mixed, briefly centrifuged, and incubated at 
2 5 ' ~  for 2 minutes. A 1p1 aliquot of Superscript 11 (200 units) was then added to each 
tube, and the tubes incubation at 2 5 ' ~  for 8 minutes. RNA mixtures are then incubated at 
5 0 ' ~  for 50 minutes to activate the reverse transcriptase enzyme and begin reverse 
transcribing RNA to cDNA, then the reactions were terminated at 7 0 ' ~  for 5 minutes to 
inactivate the enzyme. The tubes were then chilled on ice. Reactions were then collected 
by brief centrifugation, followed by the addition of 1 p1 of E. coli Rnase H to each tube 
and the tubes were incubated at 3 7 ' ~  for 20 minutes. The cDNA synthesis reaction mixes 
were then stored at - 2 0 ' ~  until use in the Polymerase Chain Reaction. 
Polymerase Chain Reaction (Control samples) 
DNA from the three control samples, CEM, MCF-7, and WIDR, was amplified using the 
Polymerase Chain Reaction as two separate fragments using four primers. Due to the 
high GC rich region of the 5' UTR region of the fpgs gene (cctugugcgc tgccgggggc 
gccgggact), which complicates the specificity of primer binQng, amplification of the 
gene as a single 1.8 kb fragment was not feasible. As an alternative, the entire coding 
region of the fpgs gene was amplified as two overlapping PCR fragments (See Figure 6). 
Two primers were designed for amplification of the first fragment (.8 kb fragment) and 
another set of primers were designed for the second fragment (1 kb fragment). Reagents 
used per 25 pl reactions were 2.5X Enhancer and 2.5X Buffer solution from InVitrogen 
Life Technologies, 2 mM MgS04, 1 uM primer, an aliquot dimethyl sulfoxide, 1 unit of 
Taq DNA Polymerase, .2 mM dNTPs, 2.5 units of Pfu DNA Polymerase, 2 p1 of cDNA, 
and 13.5 p1 of HPLC water. PCR condition were set at 94°C for 30 seconds 
(denaturing), 37 - 72°C for 30 seconds (annealing), 72°C for 30 seconds (synthesis), 35 
cycles only, 72°C for 5 minutes (final elongation) followed by 4°C storage. 
Polymerase Chain Reaction (patient samples) 
Optimum PCR condition for the first fragment was performed using primers FOR3 and 
REVSEQ8OO (See Figure 11) at 94°C for 30 seconds, 52°C for 30 seconds, 72°C for 30 
seconds, 35 cycles only, 72°C for 5 minutes, followed by 4°C storage. For the second 
fragment PCR was performed using primers FORNEW and REVNEW at 94°C for 30 
seconds, 55°C for 30 seconds, 72°C for 30 seconds, 35 cycles, 72°C for 5 minutes, 
followed by 4OC for precipitation. For the third fragment PCR was performed using 
primers FPGS RP2 and RP2. PCR conditions were set at 94OC for 30 seconds, 60°C for 
30 seconds, 72°C for 30 seconds, 35 cycles, 72°C for 5 minute, and 4°C storage. 
Agarose Gel Electrophoresis 
Once PCR was completed, samples were loaded on 1% agarose gels for viewing of 
amplication products. To constitute these gels, 1.2 g of agarose powder was mixed with 
120 ml of 1X Tris Acetate Buffer (40 mM Tris Base, 20 mM Glacial Acetic Acid, and 1 
rnM EDTA with pH - 8.0) and heated in a microwave for 1.5 minutes (mixing every 15 
seconds to dissolve agarose powder). Ethidium bromide (7.5 p1) at a concentration of 
5 pg/pl is added to the gel mixture. The mixture was then poured into a plastic tray, 
sealed with a casting tray containing a 25 well gel comb, and the gel was allowed to 
polymerize at room temperature. The comb was then removed and the plastic tray, along 
with the agarose gel, was transferred to a horizontal electrophoresis chamber containing 
Tris Acetate Buffer, needed for optimum DNA mobility. Loadng buffer (2 pl) was then 
added to 20 p1 of each sample containing PCR products and each samples was loaded 
into a well of the agarose gel. Once the lid of the electrophoresis chamber was closed, 80 
rnA current was applied to the gel for 30 minutes, allowing the PCR products to migrate 
towards the positive electrode (care is taken to make sure that the products migrate 
towards the cathode). The DNA of each sample was then briefly visualized on an 
ultraviolet transluminator. 
Gel Purification of PCR Products 
DNA band were carefully excised from an agarose gel using a scalpel and each band was 
placed in a 1.5 ml centrifuge tube. Buffer QG (300 pl), containing guanidine thiocyanate, 
was added to gel slice to facilitate melting of the agarose gel when incubated at 60°C for 
10 minutes. The gel containing the DNA band was vortexed every three minutes during 
heating until the gel was completely dissolved. Once the gel melted, 100 p1 of 
isopropanol was added to the melted gel mixture, which ultimately allows binding of the 
DNA to the column. Next, the mixture was transferred to the mini column in a centrifuge 
tube, which served as a filtering device for elution of the DNA from the melted gel 
mixture, followed by brief centrifugation at maximum speed. The eluted gel mixture was 
then &scarded and the columns were placed back in collection tubes. To wash the bound 
DNA, 0.75 ml of Buffer PE (containing ethanol) was added to the mini columns, and the 
columns were incubated at room temperature for 2 minutes, and then centrifuged at 
13,0000 rpm speed for 1 minute. Again, the flow-through was discarded and columns are 
placed back in collection tubes and centrifuged at maximum speed for 1 minute to 
eliminate any residual ethanol from the Buffer PE. Once the gel mixture has completely 
filtered through the column and the DNA was washed free of contaminants, the mini 
columns were then transferred to a clean 1.5 ml collection tube and a 40 p1 of 10 rnM 
Tris-HC1, pH 8.5 was added to the center of the column membrane, incubated for 1 
minute at room temperature, and centrifuged at maximum speed for 1 minute. This final 
step allows complete elution of clean DNA from the mini columns into the collection 
tube. 
Sequences and Analysis of PCR Products 
An aliquot (10 ng) of each sample was sequenced using 2 p1 of 5 uM Primers. 
Sequencing was done at the DNA core lab at the Medical College of Virginia and 
SeqWright and Fisher Scientific Laboratory, and Single Nucleotide Polymorphisms were 
detected using the CodonCode Aligner computer program 
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RESULTS 
Preparation of RNA from control cell lines 
Total RNA was isolated fiom the three control cell lines using the Trizol method 
(Protocol was obtained fiom the Institute of Genomic Research website at 
http://pga.tigr.org/soplM019.pdf). Following isolation, 1 pg of total RNA from each cell 
line was loaded and run on a 1% denaturing agarose gel to assess its integrity. As was 
expected of normal intact RNA, the gel image in Figure 5 displays two distinct bands. 
The lower band represents thel8S ribosomal subunit and the upper band represents the 
28s ribosomal subunit. The light smear displayed above the upper band and between the 
two main bands represents other RNA species, including all of the rnRNAs and also any 
minor RNA degradation. The prominent bands on this gel show stable RNA and adequate 
RNA concentration for our experiments. 
Preparation of RNA from patient samples 
For patient samples 1-6, RNA isolation was performed using the Quiagen method which 
required considerable less time when compared to the Trizol method (Protocol was 
obtained fiom the Institute of Genomic Research website at 
http://pga. tigr.org/soplMO 19. pdf). Residual blood samples ( 1 -2 ml) were obtained fiom 
the hematology laboratory at the Virginia Commonwealth University Hospital. Samples 
were collected in purple top tubes containing ethylenediaminetetraacetic acid (EDTA) to 
prevent blood clot formation. Samples were collected fiom patients with a white blood 
cell count of at least four, to ensure that sufficient RNA would be available to perform 
multiple PCR reactions. Once RNA was extracted from samples 1-6, 1p1 of 50 p1 of total 
RNA was loaded and run on a nanochip of .the Agilent 2 100 Bioanalyzer. The Agilent 
2100 Bioanalyzer then displayed a virtual gel, which represents a 1% denaturing agarose 
gel as it would appear with the same concentration of RNA from each sample. A 
representative sample of the virtual gels is illustrated in the upper left hand corner of 
Figure 6, with the 150 nglpl ladder shown in the first lane. Like thel% denaturing 
agarose gel, the Agilent 2100 Bioanalyzer produces an electropherogram displaying two 
peaks, the shorter peak representing the 18s ribosomal unit and higher peak representing 
28s ribosomal subunit. The first peak to the far left of each electropherogram represents 
the 25-nucleotide marker added to each sample. RNA integrity and concentration was 
determined according to the height of each peak, as well as by the amount of small peaks 
between the two major peaks. Sample 4, for example, has less RNA degradation than 
sample 5, as is evident by the increased amount of smaller peaks that exist between the 
two major peaks of sample 5. (See Figure 6). 
Gel PCR products of control samples (800 bp and 1 kb) 
Once RNA was isolated from the control samples and first stand cDNA synthesis was 
performed, amplification of the figs gene was performed using the polymerase chain 
reaction (PCR). DNA from the three control samples was amplified into two separate 
fiagrnents using two sets of primers. Due to the high GC rich region of the 5' UTR 
region of the figs gene, amplification of the gene as a single 1.8 kb fragment was not 
feasible. A 24 p1 reaction of the PCR products from each cell line was loaded and run on 
a 1% agarose gel for 30 minutes. In Figure 7, the first 800 bp fragment amplified from 
each control cell line is displayed in lanes 1-6, with 24 p1 reactions from each cell line 
loaded into two wells (for example, 24 p1 PCR products from the CEM cell line was 
loaded into lanes 1 and 2). The bands representing the 1 kb fragments for each cell lines 
in lanes 7-9 are not as abundant as those representing the 800 bp fragments. Furthermore, 
the lower bands in lanes 7-12 represent primer dimer formation, which show decreased 
primer specificity for the DNA templates. However, due to the fact that I loaded 48 p1 
reaction for each cell line (24 pl in each well), I had sufficient PCR products for 
sequencing. 
PCR and Sequencing primers used for 800 bp and 1 kb fragments 
The primers used for amplification and sequencing of the two fragments of the control 
samples are shown in Figure 8. Two sets of primers were used for amplification and 
sequencing of each fragment. The first 800 bp fragment was amplified using forward 
primer FOR3, which starts 32 nucleotides upstream of the mitochondnal start site and 
ends at nucleotide 3. The reverse primer, MR2 starting at nucleotide 885 and ending at 
nucleotide 864 was also used to amplify the first 800 bp fragment. The 1 kb fragment 
was amplified using forward primer MF1, which starts at nucleotide 809 and ends at 
nucleotide 826. Thus, the sequences of the two PCR fragments overlap by 38 nucleotides. 
The reverse primer, RP2 starts at nucleotide 1814 and ends at nucleotide 1837. 
Sequencing of the 800 bp fragment was performed using primers For6 and F2lasn. 
Primers FORSEQ 1 kb and REVSEQ 1 kb were used to sequence the 1 kb fragment. 
Amplification of samples 1-6 
Following amplification and sequencing of the two fragments of the control samples, 
PCR was then performed on patient samples 1-6. Figure 9 displays the PCR products of 
the first 800 bp fragment of samples 1-6. Again, 24 pl of PCR product from each patient 
sample was loaded into 2 separate wells. Sample 2 was loaded into 3 separate wells 
following repeated PCR. Primer dimers (low molecular weight bands formed on the 
bottom of the agarose gel) were removed during gel purification. The patient samples 
proved to be more difficult than the control samples. Because human peripheral blood 
cells have a limited amount of the fpgs rnRNA, I first experienced difficulty amplifLing 
the gene in 2 fragments, then I experienced further difficulty sequencing the PCR 
products. Before we began this project, we anticipated some dificulty obtaining 
sufficient fpgs RNA from human peripheral blood. We then decided to amplifj the f'pgs 
gene into 3 fragments with the first fragment at 465 nt, the second at 964 nt and the third 
at 615 nt in length. Six primers were designed for PCR and 4 primers were designed for 
sequencing (See Figure 11). This solved the PCR amplification problem, as well as the 
sequencing problem. An example of a good versus poor sequencing run is illustrated in 
Figure 10. 
Amplification of 465 bp fragment of the fpgs gene 
Once I began amplification of thefigs gene into three fragments, I obtained better results. 
Figure 13 is an image of the most upstream 465 bp PCR product from samples 1-1 3. An 
aliquot of 10 pl reactions was loaded on to the 1% agarose gel and 80 mA of current was 
applied to the gel for 30 minutes. While some of the PCR products produced sharp 
bands, others such as samples 1 and 9 were later repeated to obtain a greater 
concentration of PCR products. Sequencing of the PCR products was performed using 
reverse primer, REVSEQSOO, as illustrated in Figure 1 1. 
Amplification of the 964 bp fragment 
The 964 bp fragment of the fpgs gene was amplified using forward primer, FORNEW 
and reverse primer REVNEW. Sequencing was performed using MF1 primer and RMD 
primer. Figure 14 is an illustration of the middle 964 bp fragment of samples 1-18, 
loaded and run on the 1% agarose gel following PCR. Primer dimers are removed during 
gel purification. PCR products of samples, such as sample 3 and 5, were later repeated to 
obtain a greater amount of product needed to obtain good sequencing results. 
Amplification of downstream 615 bp fragment 
Figure 15 displays the downstream 615 bp PCR product of samples 1-8, loaded and run 
on the 1% agarose gel. This fragment of the fpgs gene was amplified using forward 
primer FPGS RP2 and reverse primer RP2. Sequencing was performed using reverse 
primer RP2. Despite the primer dimers that formed in each PCR reaction, we were able 
to obtain sufficient amount of the PCR products for sequencing. Again, primer dimers are 
removed during gel purification. 
Fig 5. RNA of all 3 control cell lines 
Total RNA (1 pg) of the three control cell lines, CEM, MCF-7, and WiDr, were loaded 
and run on a 1% denaturing agarose gel1 at 80 mV for 30 minutes. Upper bands represent 
18s ribosomal RNA subunit and lower bands represent 28s ribosomal RNA subunit. The 
appearance of 2 dstinct bands shows intact stable RNA. 
CEM MCF-7 
Fig. 5 
Fig 6. Ribosomal RNA subunits of samples 1 - 6 displayed by Agilent 2100 
Bioanalyzer 
Electropherogram display of peaks representing 18s and 28s ribosomal RNA subunit of 
total RNA from patient samples 1- 6. The first peak of each electropherogram represents 
an aliquot of marker that was loaded into each sample. The lower peak represents the 18s 
ribosomal RNA subunit and the higher peak represent the 28s ribosomal RNA subunit. 
The smallest minor peaks shown between the 18s and 28s peaks represent any RNA 
degradation in the samples. The image below is an illustration, displayed by the Agilent 
2100 Bioanalyzer, of a virtual denaturing gel of total RNA from samples 1-6. The left 
most lane represents the 150 ng/p1 ladder and lanes 1-6 represents samples 1-6. The 
ladder has 6-7 peaks of different sizes, which calibrates the instrument, allowing correct 
measurement of the 18s and 28s ribosomal RNA peaks in each samples. 
Fig. 6 

Fig 7. PCR product of control cell lines (800 bp and 1 kb) 
A Display of the 800 bp and 1 kb PCR products of control cell lines, CEM, MCF-7, and 
WiDr is shown in figure 7. The 1 kb ladder (8 p1) was loaded into the first lane and the 
800 bp PCR products of the three control lines were loaded into lanes 7 - 12. The low 
molecular weight bands formed at the bottom of the agarose gel illustrate primer dimers 
formed during PCR. 
Lane L = Ladder 
Lanes 1,2 = CEM (800 bp) 
Lanes 3,4 = MCF-7 (800 bp) 
Lanes 5,6 = WiDr (800 bp) 
Lanes 7,8 = CEM (1 kb) 
Lanes 9,10 = MCF-7 (1 kb) 
Lanes 11,12 = WiDr (1 kb) 
Fig. 7 
Fig 8. Primers used for PCR and sequencing of two fragments of the control 
samples 
A set of primers were used for sequencing of the 800 bp and 1 kb fragments of the figs 
gene. The 800 bp fragment was amplified using forward primer FOR3 and reverse 
primer MR2. The 1 kb fragment was amplified using forward primer MFI and reverse 
primer RP2. A separate set of primers was used to sequence the 800 bp and 1 kb PCR 
products of the figs gene. The 800 bp fragment was sequenced using forward primer 
For6 and reverse primer F2 lasn. The 1 kb fragment was sequenced using forward primer 
FORSEQ 1 kb and reverse primer REVSEQ 1 kb. 
Primer Sequence Reverse or Forward Position in Sequence 
800 bp fragment 
For3 S'GCCGGGGGCGCCGGGACTATG 3' Forward -32-3 
MR2 5' CTCTATACCTGTGCCGATGC 3' Reverse 864-885 
1 KB fragment 
MF 1 5' CCAGCAGATCTCATGTC 3' Forward 809-826 
RP2 5' GCACCTAGTATGTAAGTTCATGG 3' Reverse 1 8 14- 1 837 
Sequencin~ primers: 
800 bp fragment 
For6 5' CCGAGCATGGAGTACCA 3' Forward 121-137 
F2 lasn 5' GGTACAGTTCCATGGCTTCC 3' Reverse 228-247 
1 KB fragment 
FORSEQ 1 kb 5' AACCTGACAGAGGTGTCATCC 3' Forward 1 32 1 - 1 34 1 
REVSEQ 1 kb 5' CCAGTGTCACTGTGAAGTTC 3' Reverse 1361-1381 
Fig. 8 
Fig 9. PCR products of samples 1-6 (800 bp) 
The 800 bp PCR fragments from samples 1 - 6 were loaded and run on 1% agarose gel 
at 80 mV for 30 minutes. The 1 kb ladder (8 p1) was loaded into the first lane and 24 p1 
of the 800 bp PCR products of each sample was loaded into 2 separate wells in lanes 1 - 
10. Sample 2 was repeated and loaded into three separate wells. The negative control 
was loaded into the second lane of the bottom gel (lane N). 
Lanes 1,2 = sample 1 (800 bp) 
Lanes 3,4 = sample 3 (800 bp) 
Lanes 5,6 = sample 4 (800 bp) 
Lane N= negative 
Lanes 1 1,12,13 = sample 2 (800 bp) 
Lanes 7,8 = sample 5 (800 bp) 
Lanes 9,10 =sample 6 (800 bp) 
Lane L = Ladder 
Fig. 9 
Fig 10. Good and poor sequencing results of 1 kb fragment of samples 1-6 
The top figure is an illustration of a chromatogram of the 1 kb PCR product of one 
sample that was poorly sequenced. The lower chromatogram figure shows an example of 
a successful sequencing run performed on the 800 bp PCR product of one of the samples. 
In the bottom chromatogram, the peaks of the raw data are distinguishable in height and 
color. Unlike the top chromatograrn, the program was able to successfully label each 
peak with the appropriate nucleotide. Furthermore, there is little to no background peaks 
in the bottom chromatograrn, which eliminates any chance of misinterpreting sequencing 
errors for a single nucleotide polymorphism. 
Fig. 10 
Fig 11. Primers used for PCR and sequencing of the three fragments of the fpgs gene 
Three sets of primers were used for sequencing of the 465 bp, 964 bp, and 615 bp 
fragments of thefpgs gene. The 465 bp fragment was amplified using forward primer 
FOR3 and reverse primer RevSeq800. The middle 964 bp fragment was amplified using 
forward primer FORNEW and reverse primer REVNEW. The downstream 615 bp 
fragment was amplified using forward primer FPGS RP2 and reverse primer RP2. A 
separate set of primers was used to sequence the three PCR fragments of the figs gene. 
The upstream 465 bp fragment was sequenced using reverse primer RevSeq800 and the 
middle 964 bp fragment was sequenced using forward primer MF1 and reverse primer 
RMD. The downstream 61 5 bp fragment was sequenced using reverse primer RP2. 
PCR Primers 
Primer Sequence Reverse or Forward Position in Sequence 
Upstream 465 bp 
For3 GCCGGGGGCGCCGGGACTATG Forward -3 2 -3 
RevSeq800 TGAAGAGCTCAGGACTGATGG Reverse 437-458 
Middle 964bp 
FORNEW AAGCTATGGCCTGAAGACGGGATT Forward 657-380 
REVNEW AGGGCAGAAGACGGCATAGTCAAA Reverse 1297-1320 
Downstream 615 bp 
FPGS RP2 GTTCGAGTCTTGCTCTTCAATGCTAC Forward 1322-1347 
RP2 GCACCTAGTATGTAAGTTCATGG Reverse 1814-1837 
Sequencing Primers 
Upstream 465 bp 
RevSeq800 TGAAGAGCTCAGGACTGATGG Reverse 437-458 
Middle 964 bp 
h4F1 CCAGCAGATCTCATGTC Forward 809-826 
RMD GTTCGAGTCTTGCTCTTCAATGCTAC Reverse 969-990 
Downstream 615 bp 
RP2 GCACCTAGTATGTAAGTTCATGG Reverse 1814-1837 
Fig. 11 
Fig 12. Diagram of primers used for amplification of the gene into 2 and 3 fragments 
A schematic of the PCR primers used to amplify the fpgs gene into 2 and 3 fragments is 
illustrated in Figure 12. The top figure represents the 1.8 kb cDNA construct of the figs 
when amplified into 2 fragments, an 800 bp and 1 kb fragment. The primers used to 
amplifjl the 800 bp fragment are forward primer For3 (shown in red in the top figure) and 
reverse primer MRl (also shown in red in the top figure). The 1 kb PCR fragment was 
amplified using forward primer MF1 (shown in blue in the top figure) and reverse primer 
RP2 (also shown in blue in the top figure). Following unsuccessful amplification of the 
figs gene into 2 fragments using patient samples, attempts were made to amplifL the gene 
into three fragments. The bottom figure represents the 1.8 kb cDNA construct amplified 
into 3 fragments, a 465 bp, a 964 bp and downstream 6 15 bp fragment. The primers used 
to amplify the upstream 465 bp fragment are forward primer For3 (shown in red in the 
top figure) and reverse primer Revseq800 (shown in red in the bottom figure). The 964 
bp PCR fragment was amplified using forward primer FORNEW (shown in blue in the 
bottom figure) and reverse primer REVNEW (also shown in blue in the bottom figure). 
The primers used to amplify the downstream 615 bp fragment are forward primer 
FPGSRP2 (shown in brown in the bottom figure) and reverse primer RP2 (shown in 
brown in the bottom figure). 
OverIappine PCR  rimer sequences of the 2 fragments 
Overlart~in~ PCR primer sequences of 3 framents. 
Fig. 12 
Fig 13. Example of upstream 465 bp PCR products 
The 465 bp PCR fragments from ten of the samples were loaded and run on 1% agarose 
gel at 80 mV for 30 minutes. The 1 kb ladder (8 p1) was loaded into the first lane and 24 
p1 of the 465 bp PCR products of samples 1 - 13 were loaded into each well in lanes 1 - 
13. Sample 26 and 38 were later repeated to obtain a higher concentration. 
Lane 1 = sample 25 
Lane 2 = sample 26 
Lane 3 = sample 27 
Lane 4 = sample 28 
Lane 5 = sample 29 
Lane 6 = sample 30 
Lane 7 = sample 3 1 
Lane 8 = sample 32 
Lane 9= sample 38 
Lanes 10 = sample 39 
Lane 1 1 = sample 40 
Lane 12 = sample 4 1 
Lane 13 = sample 42 
Lane L =Ladder 
Fig. 13 
Fig 14. Example of 964 bp PCR products 
964 bp PCR fragments from 18 of the samples were loaded and run on 1% agarose gel at 
80 mV for 30 minutes. The 1 kb ladder (8 pl) was loaded into the first lane and 24 p1 of 
negative control was loaded into the second lane. The 964 bp PCR products of these 
samples (24 pl) were loaded into each well in lanes 1 - 18. Sample 66 and 68 were later 
repeated to obtain higher concentrations. 
Lane N = Negative control 
Lane 1 = sample 6 1 
Lane 2 = sample 62 
Lane 3 = sample 66 
Lane 4 = sample 67 
Lane 5 = sample 68 
Lane 6 = sample 72 
Lane 7 = sample 73 
Lane 8 = sample 75 
Lane 9 = sample 76 
Lane 10 = sample 80 
Lane 1 1  = sample 82 
Lane 12 = sample 83 
Lane 13= sample 86 
Lane 14 = sample 87 
Lane 15= sample 88 
Lane 16 = sample 89 
Lane 17 = sample 90 
Lane 18 = sample 9 1 
Lane L = Ladder 
Fig. 14 
Fig 15. Example of downstream 615 bp PCR products 
The downstream 615 bp PCR fragments from eight of the samples were loaded and run 
on 1% agarose gel at 80 mV for 30 minutes. The 1 kb ladder (8 11) was loaded into the 
first lane (lane L) and 24 p1 of the 6 15 bp PCR products of each sample was loaded into 
each well in lanes 1 - 8. All eight samples were successfully amplified. 
Lane 1 = sample 44 
Lane 2 = sample 45 
Lane 3 = sample 47 
Lane 4 = sample 49 
Lane 5 = sample 5 1 
Lane 6 = sample 52 
Lane 7 = sample 53 
Lane 8 = sample 54 
Lane L = Ladder 
Fig. 15 
Chapter 4 
Detection of Single Nucleotide Polymorphisms in Fpgs Gene 
Use of the CodonCode Aligner to detect SNPs 
The CodonCode Aligner is a multifunctional user-friendly software program designed by 
the CodonCode Corporation. This program is capable of aligning sequences, editing 
sequences, and detecting mutations. Once we obtained a license for use of this program, 
sequences were imported and aligned as traces into the program folder. Once sample 
traces were aligned, we clipped the beginning and end of the sequences to remove 
undecipherable peaks (See Figure 10 for an example of unreadable sequences). The 
program also allowed viewing of the sequences in reverse complement forms, which 
optimized sequence analysis of the reverse strand. Upon alignment of the sequences, the 
program determines the consensus sequence, which it &splays at the bottom of the 
screen, labled contig 1 (See Figure 16). We then instructed the program to detect 
mutations beginning at a predetermined start codon and ending at a predetermined stop 
codon of the sequence (users may determine where to begin and end sequence analysis). 
Following sequence analysis, the CodonCode Aligner program tagged various areas of 
each sequence indicating sequence quality and mutations types, such as single nucleotide 
polymorphisms (See figure 16). The tags, which are color coded, can also be modified in 
intensity and color by the user (See figure 16). If a sequence differed by one or more 
nucleotides from the consensus sequence, the program tagged that base in the consensus 
sequence, labeled contigl in figure 16 (See figure 16). In Figure 16, for example, the 
consensus base is A/A, which is highlighted in red in sequence 29C and the consensus 
sequence (contig 1). In the bottom sequence labeled 40C, however the GIG homozygote 
allele is expressed at this position, which the program highlights in the consensus 
sequence using a red tag. So essentially, one method of detecting a SNP using this 
program was to scan the consensus sequence for tagged bases. Another method of 
detected SNPs was to scan every single sequence for tags and then analyze every tagged 
area for possible SNPs. Though extremely tedious and time consuming, ths  method 
proved to be the most effective form of sequence analysis. The program not only tagged 
mutations and poor quality peaks, but it also tagged every position where peaks were not 
as high as adjacent peaks or where peaks were not equidistance to adjacent peaks. For 
this, we spent a great deal of time analyzing tagged areas of the sequences that were 
ultimately accepted as normal sequence. It was important to analyze all tagged areas to 
ensure that no SNPS were overlooked. Figure 23, for example, shows an important SNP 
at nucleotide 1334 that sequestered in a poor quality region of the sequence. Following 
sequence analysis, repeated PCR, and repeated sequence analysis, we eliminated a large 
number of false positive SNPs. An example of a false positive is illustrated in Figure 17. 
This apparent SNP was not observed in repeat sequences over this region. Ultimately, it 
was determined that a SNP was real if the base at the position where two nucleotides 
were observed, decreased in height when compared to the base at the corresponding 
position in the wild type sequence. For example, in Figure 18 base G in the A/G SNP at 
nucleotide 64 deceased in height by approximately one-half when compared to the GIG 
wild type sequence below. Similarly Figure 19 base G in the GIA SNP at nucleotide 123 
deceased in height when compared to the G/G wild type sequence. 
SNPs Detected 
Due to the fact that the fpgs  coding sequence was amplified in three pieces, some 
fragments were more successfully amplified in some samples than in others. For 
example, 88 samples were successfully amplified for the first 465 nucleotides of the @gs 
gene, while 78 samples were successfully amplified for the middle fragment spanning 
964 nucleotides. The last 61 5 base pair fragment was successfully amplified in 85 of the 
samples. For the remaining 15-20 samples, PCR or sequencing was unsuccessful due to 
RNAI DNA instability or limited amount of RNA availability (all samples are unique to 
each patient and were available in very limited supply). Following sequencing of 
approximately 78-88 samples, polymorphic sites were found at nucleotides 64, 123,253, 
423, 1334 and 1781 (See Figure 16-21). These SNPs are summarized in table 1. 
Sequencing of the first 465 nucleotides was performed on 88 total samples. Of the first 
PCR fragment sequenced, in a total of 88 samples, 48 samples express a heterozygote 
GIA genotype at nucleotide 64 (- 55 %), 1 sample expressed the homozygote A/A at this 
site (- 1 %), and the remaining samples expressed the homozygote GIG genotype at this 
position (- 44 %). At nucleotide 123, 6 samples (samples 12, 45, 88, 90, 97, 99) 
expressed the heterozygote GIA genotype (- 7 %), and one sample (sample 74) expressed 
the homozygote A/A allele at this site (- 1 %), and 81 (- 92 %), samples express the wild 
type GIG allele. Of the 88 samples sequenced, only one sample (sample 80) expressed a 
heterozygote C/T allele at nucleotide 253 (- 1 %). SNPs that were detected in less than 
10 % of the samples were confirmed by repeated amplification and repeated sequencing 
cDNA from both directions. For the second fragment, at nucleotide 423, two samples (32 
& 97) expressed a heterozygous CIG allele (- 3 %), while the remaining samples 
expressed a homozygous C/C allele (- 97 %). At nucleotide 1334, one sample (26) 
expressed TIC allele while the remaining samples were C/C at this site (- 1 %). Again, 
this SNP was found by reamplifLing and resequencing cDNA from this sample. The 
homozygous change at nucleotide 64 encodes a conservative amino acid change from a 
valine to isoleucine. The G123A change expressed in six of the samples produced no 
change in the proline at this codon. Similarly, at nucleotide 423 the SNP observed was 
silent, that is, both wild type codon (CGC) and the mutant codon (CGG) encoded the 
amino acid, arginine. At nuclotide 253, however, a C to T base change produced a change 
from arginine to tryptophan. The heterozygote TIT allele at nucleotide 1334, expessed in 
the& gene of sample 26, caused a valine to alanine amino acid change. The G1781A 
SNP was detected downstream from the stop codon in sample 40 (- 1 %). A summary of 
these results is displayed in Table 1. 
Fig 16. Example of tagged SNPs in consensus sequence. 
A portion of the downstream 6 15 bp sequence of sample 29 and 40 is displayed in Figure 
16. The consensus sequence of this portion of the gene is also displayed at the bottom of 
the figure, labeled Contigl. Because the two sequences of samples 29 and 40 differ by 
one nucleotide at the position highlighted by the program in red, the program also 
highlights that nucleotide position in the consensus sequence displayed at the bottom of 
the screen (shown by the arrow). 
29C-fwd GCACCTGGTG GGIWGTCC TGAAGCTGCT GGAGCCCGCA CTWCCCAGT AGCCMGGCC C G M T G A R  GGTGGGAGCT T(XWAEP -
Contigl GCACCTGGTG GGTGTGTCC TGAAGCTGCT GGAGCCCGCA CTGTCCCAGT AGCCAAGGCC CGGGGTTGAA GGTGGGAGCT TCCCACACCT 
4OC-fwd GCACCTGGTG G@WTGTCC TGARGCTGCI GGAGCCCW CTGTCCCAGT AGCCAAGGCC ~4 ETGGGAGCT WCAACCf 
Fig. 16 
1451 1461 1471 1481 1491 1501 1511 521 h1 
Fig 17. Example of false positive SNPs 
False positive SNPs fkequently appeared during sequence analysis. This false positive 
shown in the top chromatogram and highlighted in green by the Codoncode Aligner 
program originally appeared to be a SNP because of the double peak at this position 
(shown by the arrow) as well as the lack of background sequencing error in adjacent 
peaks. This SNP, however, did not appear during repeated sequence analysis of repeated 
PCR products. 
4 T G C C  - G T  
G T G C G C A  
150 
\ T G  C C G T G C G C A  
10 I 150 
Fig. 17 
Fig 18. SNP 64 AIG Valine/Isoleucine 
SNP 64 is highlighted by the Codoncode Aligner program in the top chromatogram. 
There are no background sequencing errors, which optimizes sequence analysis and 
accuracy. The lower three chromatograms have a single peak at nucleotide 64, 
representing either the homozygote A/A or GIG Allele. The peaks of these lower four 
chromatograms are approximately double the height of the peak in the chromatogram of 
the heterozygote GIA SNP. 
1. Heterozygote GIA 
X G C A T A A  CGA 
: O O C  T A A  CGA 
~1 
2. Homozygote A/A 0 
3. Homozygote GIG  
4. Homozygote GIG / 
Fig. 18 
Fig 19. SNP 123 A/G Prolineff roline 
SNP 123 is highlighted in the first three chromatograms below, while the wild type 
homozygote GIG allele is displayed in the bottom chromatogram. The homozygote A/A 
S N P  is shown in the second chromatogram. Again, there are no background sequencing 
errors, optimizing sequence analysis and accuracy, and the peaks of the homozygote 
alleles are higher than the peaks of the heterozygote alleles. 
1. Heterozygote GIA / 
2. Homozygote A/A  
3. Heterozygote G/A 
4. Homozygote GIG / 
Fig. 19 
Fig 20. SNP 253 C/T Argininemryptophan 
SNP 253, which caused an arginine to tryptopan amino acid change, is displayed in 
chromatogram 1. This SNP caused a C to T base change in the ACG nucleotide triplet 
coding for the aarginine amino acid. Chromatogram 2 and 3, in the figure below, shows 
the homozygote TIT wild type allele. 

Fig 21. SNP 423 CIG ArginineIArginine 
Chromatograms 1 and 2 in the figure below show SNP 423, which caused a C to G base 
change in the CGC codon. The wild type homozygote CIC allele is displayed in the 
chromatogram 3. The heterozygote C to G base change did not change the arginine 
amino acid coded by the CGC nucleotide triplet. 
' i c y ~  C A A T G G  
50 
T C C G C A T C A  A T G G  
40 I 50 
1. Heterozygote C/G c 
2. Heterozygote CIG 1 
3. Homozygote CIC 
Fig. 21 
Fig 22. SNP 1334 C/T ValineIAlanine 
SNP 1334, which caused a valine to alanine amino acid change is displayed in 
chromatogram 1. This SNP caused a C to T base change in the CTG nucleotide triplet 
coding for the valine amino acid. Chromatogram 2, in the figure below, shows the 
homozygote TIT wild type allele and chromatogram 1 shows the homozygote CIC allele. 

Fig 23. SNP 1781 A/G 
SNP 1781 in figure 23 resulted n a homozygote A to G base change. The heterozygote 
A/A alleles are displayed in chromatograms 1 and 4, and the wild type A/A alleles are 
displayed in chromatograms 2 and 3. Because this SNP is located downstream fiom the 
stop codon, no amino acids are translated by the ribosomal RNAs. 
Fig. 23 
Table 1 .  
Detected Human fpgs SNPs 
nt SNP 
64 AIG 
123 GI A 
253 C/T 
423 C/G 
1350 CIG 
1781 GIA 
Codon Change Amino Acid Change 
ATA > GTA Isoleucine> Valine 
CCG > CCA Proline (no change) 
ACG > ACG Arginine > Tryptophan 
CGC > CGG Arginine (no change) 
AAC > AAG Asparagine > Lysine 
GGA > GAA --- 
Table 2. 
Humanfpgs SNPs of the NCBI database 
Entry number Sequence Comment 
TAAG[M]TGCA Not found on the FPGS genomic locus by 
Blast search 
htron 
Intron 15 
Intron 
GcGG[A/C]GTAA Exon 1 
CTAC[-IAIAAAA Intron 14 
ATAG[CKJTGGG Intron 16 
ACAT[CmTCAG Intron 10 
AATA[AIG]GGTG Intron 5 
TTGC[CWCTAG Tntron 1 
g c a c [ W a g  Intron 5 
CGGC[A/G]TAAC Exon 1 
aatt[A/G]ttag Intron 
Random sequence 
437 V>D Checked in 209 
samples, never 
found. Sequencing 
error 
2 1 G>G Random sequence 
22 I>V nt 64 (again) 
rs10118903 
gene by Blast 
tctc[-/AA]aaaa Intron 15 
gg=[NG]aggca Intron 5 
W i P [ ~ I g c c g  Intron 5 
g5~[NGIaagc Intron 5 
CCAG[A/G]AGTG W o n  1 
TGGT[CfqGGTG ? 
l'TTT[G/TlGGTT Intron 12 
gtct[C/Tltaca Intron 15 
@gt[G/Tlm Intron 15 
ACCT[NG]CTAT Intron 1 
~ @ g w ' ] @  Intron 15 
cac t [C/T]gaac Intron 9 
GGGC [A/G]GGGC Intron 13 
tW-/Tlgaga Intron 5 
ATAC[A/C]CATT Exon 1 5 
Not found on the FPGS 
analysis 
Confirmed in 209 
individuals. AAIAGIGG = 
.885/.09 11.024 
Confirmed in 
354 samples. 
AAIACICC = 
.065/.234/.333 
The remaining 
.367allelic 
frequencies 
was 
unspecified 
(see NCBI 
Database) 
AAGG[CR]TGGG Intron 2 
CCTT[CqTGGG exon 15 
Intron 5 
GAT A[A/G]C AGA Intron 
ATCA[G/T]GGGT Intron 1 
GCC A[A/G]GAGG Exon 15 
294 P A  Confirmed. 23 
samples 
AAIAG - 
.957/.043 
Checked in 204 samples. 
No SNP found at this nt. 
Error in reference sequence 
Checked in four studies, 
three had 100 % CCs in all 
30 samples; the other had 
100 % GG in all 47 
samples 
3'-UTR. Checked in 42 1 individuals. 
AA/AG/GG = .221/ .480/ 
.299 
DISCUSSION 
Previous studies by Barredo, J et a1 showed that while substantial levels of thefigs gene 
was expressed in lymphoblasts from patients with acute lymphoblastic leukemia, no 
expression of this gene was detected in circulating granulocytes, erythrocytes, and 
lymphocytes (23). In this experiment, however, we were able to successfully detect RNA 
expression in monocytes and lymphocytes. The discrepancy in both these results has 
much to do with the difference in techtuques being used to detectfigs expression. While 
Barredo, J et a1 used a protein enzyme assay technique to detect FPGS activity, in this 
experiment we first extracted the RNA from the mononuclear cells then used Polymerase 
Chain Reaction to amplify the gene. PCR is a much more sensitive technique than an 
enzyme assay technique for detecting RNA expression. With as little as 1 pg of DNA, we 
were able successfully amplify and sequence 85 % of thefpgs gene in the mononuclear 
cells of the hurnan peripheral blood. Barredo, J et a1 did not have the benefit of using the 
PCR technique for detecting figs RNA expression in mononuclear cells because the 
sequence of thefpgs gene, which was required for designing primers, was not yet known. 
With the advantages of PCR and the availability of thefpgs gene sequence we were able 
to detect and confirm, by repeated testing, six single nucleotide polymorphisms expressed 
in the fpgs gene, of the peripheral blood, of 85 normal human subjects. These single 
nucleotide polymorphisms are located in a variety of different regions of thefigs gene. 
One SNP was detected in the mitochondnal leader sequencing, another was detected 
downstream of the stop codon, whle the other four SNPs were detected within the 
cytosolic coding sequence of the protein. The only frequently observed SNPs in the 
coding region were in the mitochondnal leader sequence. SNPs downstream of the 
cytosolic start methionine were rare. 
The first SNP ( N G )  at nucleotide 64 caused a base change in the first position of the 
codon, resulting in a valine to isoleucine amino acid change. This SNP, which was 
previously reported by Freemantle et al. was detected in a majority of the samples 
(49/88). The valine to isoleucine amino acid change, caused by a conservative point 
mutation, is expected to have little to no effect on the structure and function of the 
protein. Furthermore, this SNP is located in a region upstream of the cytosolic start site, 
and so is not expected to significantly affect catalytic function, although it might well 
affect the efficiency of mitochondnal entry. 
The second most frequently detected SNP, which was expressed in the third position of 
the codon at nucleotide 123, did not change the proline amino acid at that position of the 
polypeptide. Six of the samples expressed the GIA heterozygote allele at nucleotide 123, 
while only one sample expressed the homozygote AIA allele. Because this SNP did not 
change the amino acid, no change in protein structure and function would be expected. 
Similarly, SNP 423 also caused a base change in the third position of the codon, which 
did not change the arginine amino acid located at that position in the growing 
polypeptide. The remaining three SNPs, however, alter the codon sequence, which 
resulted in a nonconservative change in the amino acids. One of these SNPs, C253T, 
caused a base change at nucleotide 253 in the first position of the codon, replacing an 
arginine amino acid with tryptophan, a more bulky amino acid. This amino acid 
conversion, which was detected in one of the 88 samples, might affect the chemical 
nature of ,the enzyme, and would presumably alter the enzymatic activity of the fpgs 
protein. Similarly, SNP T1334C, which caused a base change at the second position of 
the codon, resulted in a valine to alanine amino acid change in the polypeptide chain. 
The final SNP was detected at position 1781 (GIA) at the second position of the 
nucleotide triplet, falling outside of the reading fiame of the fpgs gene. Normally amino 
acids translated outside of the reading frame of the gene do not play a role in protein 
function, however, SNP 1781 might affect the stability of the mRNA or the efficiency of 
polyadenylation of the message. 
There have been limited studies done on polymorphisms in the human fpgs gene, and 
very little is known about the effects of any polymorphisms in the gene that may alter 
clinical response to antifolate therapy. The next major step of this project it to analyze 
the effects of polymorphisms detected in the fpgs gene on response rate to cancer 
chemotherapy. Cells, which are mutant for the fpgs gene, will be transfected with fpgs 
gene construct expressing known polymorphic sites. These cells with then be observed 
for change in enzymatic activity of the gene. 

List of References 
1. Kwok, P.Y, Gu, Z. Single nucleotide polymorphsm libraries: why and how are we 
building them? Mol Med Today 12: 538-43 (1999). 
2. Ewing, B and Green, P. Analysis of expressed sequence tags indicates 35,000 human 
genes. Nature Genetics 25,232-234 (2000). 
3. Pennisi, E. The Human Genome. Science 16: 1 177- 1 1 80 (200 1) 
4. Freemantly, S.J and Morgan R.G. Transcription of the Human Folylpoly-gamma- 
glutamate Synthetase Gene. J. Biol. Chemistry 40: 25373-25379 (1997). 
5. Morgan R.G. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with 
tetrahydrofolate antimetabolites: an overview. Semin Oncol. 26: 24-32 (1999). 
6. Sharp, L, Little, J. Polymorphsms in Genes Involved in Folate Metabolism and 
Colorectal Neoplasia: A HuGE Review. American Journal of Epidemiology 159: 
423-443 (2004). 
7. Frost P, Blom H.J, Milos R, et al. A candidate genetic risk factor for vascular disease: 
a common mutation in methylenetetrahydrofolate reductase. Nut Genet 10: 1 11-1 13 
(1995). 
8. Botto L.D, Yang Q. 5,lO-Methylenetetrahydrofolate reductase gene variants and 
congenital anomalies: a HuGE review. Am J Epidemioi 151 : 862-877 (2000). 
9. Van der Put J, Van der Molen E.F, Kluijtrnans L, et al. Sequence analysis of the coding 
region of human methonine synthase: relevance to hyperhomocysteinaemia in 
neural-tube defects and vascular disease. QJM 90: 5 1 1-5 1 7 (1 997). 
10. Ma J, Stampfer M.J, Christensen B, et al. A polymorphism of the methionine 
synthase gene: association with plasma folate, vitamin BI2, homocyst(e)ine, and 
colorectal cancer risk. Cancer Epidemiol Biomurkers Prev 8: 825-829 (1999). 
1 1. Ulrich C, Karnpman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR 
polymorphism: evidence for gene-environment interaction? Cancer Epidemiol 
Biomarkers Prev 8: 659-68 (1 999). 
12. Ma J, Stampfer MJ, Chstensen B, et al. A polymorphism of the methionine synthase 
gene: association with plasma folate, vitamin Bl2, homocyst(e)ine, and colorectal 
cancer risk. Cancer Epidemiol Biomarkers Prev 8: 825-9 (1 999). 
13. Weitman S, Weinberg A, Coney L, Zurawski R, Jennings S and Kamen A. Cellular 
localization of the folate receptor: potential role in drug toxicity and folate 
homeostasis. Cancer Research 52: 6708-67 1 1 (1992). 
14. Anthony, A.C, Kane M.A, Portillo R.M, Elwood P.C, Kolhouse J.F. Studies of the 
role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate 
by cultured human KB cells. J. Biol. Chemistry 260: 149 1 1-149 17 (1 985). 
15. Costi, M.P and Ferrari, S. Update on Antifolate Drug Targets. Current Drug Targets 
2: 135-166 (2001) 
16. Bolin J.T, Filman D.J, Matthews D.A, Hamlin R.C and Kraut, J. Crystal structures of 
Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A 
resolution. I. General features and binding of methotrexate. J. Biol. Chem. 257: 
13650-13662 (1982). 
17. Farmgia, D, Ford, H, Cunningham, D,. Danenberg, K, Danenberg, P, Brabender, J, 
McVicar, D, Aherne, W, Hardcastle, A, McCarthy, K and Jackrnan A, Thyrnidylate 
synthase expression in advanced colorectal cancer predicts for response to 
raltitrexed.Clin Cancer Res. 9: 792-801 (2003). 
18. Taylor, E, Kuhnt, D, Shih, C, Rinzel, S, Grindey, G, Barredo, J, Jannatipour, M and Moran, 
R. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2- 
amino-3,4-dihydro-4-0~0-7H-pyrrolo[2,3-d]pynimidin-5- yl)ethyl]benzoyl]-L- 
glutamic acid, is an inhibitor of thyinidylate synthase. J.  Med Chem35: 4450-4454 
(1992). 
19. Zhao, R, Titus, S, Gao, F, Moran, R and Goldrnan, D. Molecular analysis of murine 
leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino 
acids critical to the function of folylpolyglutarnate synthetase. Gene. J. Biol. 
Chemistry 275: 26599-26602 (2000). 
20. Schuler, G.D., Boguski, M.S., Stewart, E.A., Stein, L.D., Gyapay, G., Rice, K., 
White, R.E., Rodriguez-Tome, P., Aggarwal, A., Bajorek, E., et al. 1996. A gene map 
of the human genome. Science 274: 540-546. 
21. Taylor S.M, Freemantle S.J, and Moran R,G. Structural organization of the human 
folypoly-gamma-glutamate synthetase gene: evidence for a single genomic locus. 
Cancer Research 55: 6030-6034 (1 995). 
22. Sun, X, Bognar, AL. Baker, Edward N, and Smith C.A. Structural Homologies with 
ATP-binding and Folate-binQng enzymes in the structure of Folylpolyglutamate 
Synthetase. Biochemistry 95,6647-6652 (1998). 
23. Barredo J, Moran RG. Determinants of antifolate cytotoxicity: folylpolyglutamate 
synthetase activity during cellular proliferation and development. Mol Pharmucol. 42 
687-94 (1992). 
